


Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 1


PXRD traces of Sildenafil mono-citrate, hemi-citrate lower and higher hydrates



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 2


PXRD analysis of sildenafil hemi-citrate higher hydrate



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 3

PXRD analysis of sildenafil hemi-citrate lower hydrate




Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

}

Figure 4


<sup>1</sup>H NMR of sildenafil hemi-citrate lower hydrate



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 5


Water Sorption Isotherm for Sildenafil Hemi-Citrate at 30°C



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 6


Water Sorption Isotherm for Sildenafil Hemi-Citrate at 30°C, 35 – 60%RH Range.  
Illustrating Hydration Kinetics at 50%RH.



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 7


TGA Analysis of Solid Form of Sildenafil Hemi-Citrate Higher Hydrate



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 8


Hot stage PXRD analysis of sildenafil hemi-citrate higher hydrate



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 9


PXRD analysis of Sildenafil hemi-citrate higher hydrate at ambient conditions and  
under vacuum conditions



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 10


PXRD traces of slurries of Sildenafil citrate at different pH's



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 11


PXRD analysis of solid obtained from Example 4 (in phosphate buffer) versus  
anhydrous sildenafil citrate



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 12


DSC Trace of solid from Example 4



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 13


TGA Analysis of Solid From Example 4



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 14

EGA trace for Solid from Example 4 showing the detection of water (mass ions 17 and 18) and Carbon dioxide (mass ion 44)




Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

}

Figure 15


Hot stage PXRD analysis of solid from Example 4



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 16

PXRD analysis of Solid from Example 4 at different humidities



Christopher Ian Dallman, et al.  
PC25687A  
CRYSTALLINE THERAPEUTIC AGENT

Figure 17

PXRD analysis of further hydrated form of Sildenafil Citrate observed at 40% RH

